Blueprint Medicines Corp (BPMC) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
BPMC currently has 64.1M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 2.81% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Jul 18, 2025 |
POS AM filing: Blueprint Medicines Corporation is withdrawing from registration all securities registered pursuant to the Registration Statements that remain unsold as of the date hereof due to the merger with Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis. |
64M | 0 |
| May 01, 2025 |
10-Q filing | 64.1M shares outstanding |
64M | 0 |
| Feb 13, 2025 |
10-K filing | 62.9M shares outstanding |
63M | 0 |
| Dec 18, 2024 |
8-K filing: Blueprint Medicines Corporation filed a petition in the Court of Chancery seeking the validation of the Company's 2024 Stockholder Actions due to a miscalculation of the record date for the 2024 Annual Meeting, which may affect previously granted equity awards. |
63M | 0 |
| Oct 30, 2024 |
10-Q filing | 63.4M shares outstanding |
63M | 0 |
| Aug 01, 2024 |
10-Q filing | 62.9M shares outstanding |
63M | 0 |
| May 02, 2024 |
10-Q filing | 61.6M shares outstanding |
62M | 0 |
| Feb 15, 2024 |
10-K filing | 60.6M shares outstanding |
61M | 0 |
| Oct 26, 2023 |
10-Q filing | 60.7M shares outstanding |
61M | 0 |
| Aug 02, 2023 |
10-Q filing | 60.5M shares outstanding |
61M | 0 |
| May 04, 2023 |
10-Q filing | 60.1M shares outstanding |
60M | 0 |
| Feb 16, 2023 |
10-K filing | 59.6M shares outstanding |
60M | 0 |
| Nov 01, 2022 |
10-Q filing | 59.8M shares outstanding |
60M | 0 |
| Aug 02, 2022 |
10-Q filing | 59.6M shares outstanding |
60M | 0 |
| May 03, 2022 |
10-Q filing | 59.3M shares outstanding |
59M | 0 |
| Feb 17, 2022 |
10-K filing | 58.5M shares outstanding |
59M | 0 |
| Oct 28, 2021 |
10-Q filing | 58.6M shares outstanding |
59M | 0 |
| Jul 29, 2021 |
10-Q filing | 58.4M shares outstanding |
58M | 0 |
| Apr 29, 2021 |
10-Q filing | 58.3M shares outstanding |
58M | 0 |
| Feb 17, 2021 |
10-K filing | 56.2M shares outstanding |
56M | 0 |
| Oct 29, 2020 |
10-Q filing | 55.2M shares outstanding |
55M | 0 |
| Jul 30, 2020 |
10-Q filing | 54.3M shares outstanding |
54M | 0 |
| Jul 14, 2020 |
8-K filing: Blueprint Medicines Corporation issued and sold 1,035,519 shares of its common stock to Roche Holdings in a private placement at a purchase price of $96.57 per share, receiving approximately $100 million in gross proceeds. ($100.0M proceeds) |
54M | 0 |
| May 06, 2020 |
10-Q filing | 54.2M shares outstanding |
54M | 0 |
| Feb 13, 2020 |
10-K filing | 49.3M shares outstanding |
49M | 0 |
| Jan 23, 2020 |
8-K filing: Blueprint Medicines Corporation entered into an underwriting agreement for a public offering of 4,710,144 shares of common stock at $69.00 per share, with an option for the underwriters to purchase an additional 706,521 shares. ($325.0M proceeds) |
N/A | 0 |